SyqeAir Inhaler:

A Metered-Dose Medical Cannabis Inhaler that enables fast reduction of the intensity of chronic neuropathic pain and improvement in sleep quality with minimum psychoactive adverse effects.

TGA-approved medicinal cannabis vaping devices (listed on the Australian Register of Therapeutic Goods – ARTG)

The SyqeAir Inhaler is a groundbreaking technology developed by the Israeli med-tech company Syqe®. With the company’s vision to reduce the pain and suffering of as many patients as possible in the fastest possible way, it holds over 160 patents for its innovative technology: the first metered-dose Inhaler for medical cannabis that manages to:

• Turn unreliable cannabis treatment into a stable and consistent treatment
• Overcome the risk of overdose – by delivering the lowest possible dose
• Minimize (or even eliminate) side effects
• Equip doctors with a device for medical cannabis administration that adheres to the standards of the world of medicine

Treatment using the Inhaler is supported by clinical trials, real-world evidence, and patient testimonials.
Syqe® is the first Israeli company to receive the European Union Good Manufacturing Practice standard (EU-GMP) for the production of a cannabis product for inhalation use.